2024
Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
Vandekerkhove G, Giri V, Halabi S, McNair C, Hamade K, Bitting R, Wyatt A. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precision Oncology 2024, 8: e2300654. PMID: 38547422, PMCID: PMC10994438, DOI: 10.1200/po.23.00654.Peer-Reviewed Original ResearchConceptsClinical genomic testingGenomic testingProstate cancerTumor tissuesPoly (ADP-ribose) polymerase inhibitorsPlasma cell-free DNAHereditary cancer implicationsLow tumor fractionAdvanced prostate cancerDNA damage repair genesHealth care professionalsCell-free DNANonpathogenic variantsPatient's germlineOptimal patient careSomatic alterationsSubclonal alterationsClinical decision makingClonal hematopoiesisCare professionalsGenotyping testPoor prognosisTumor fractionPatient careCancer management
2022
Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing
Giri V, Hartman R, Pritzlaff M, Horton C, Keith S. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology 2022, 6: e2200234. PMID: 35666082, PMCID: PMC9200399, DOI: 10.1200/po.22.00234.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanGenes, BRCA2Genetic TestingGerm CellsHumansMaleMiddle AgedProstatic NeoplasmsConceptsGermline testingAA menWhite menHereditary cancer assessmentStandard clinical testingCohort of menAfrican American menGermline evaluationMultivariable analysisClinical managementBorderline associationLP variantsVariant statusClinical testingGermline analysisPanel testingRate of variantsCare deliveryVariant spectrumGenetic testingCancer assessmentUncertain significanceDNA repair genesGenetic counselingAmerican men
2016
Familial prostate cancer
Giri V, Beebe-Dimmer J. Familial prostate cancer. Seminars In Oncology 2016, 43: 560-565. PMID: 27899188, PMCID: PMC6986340, DOI: 10.1053/j.seminoncol.2016.08.001.Peer-Reviewed Original ResearchConceptsFamilial prostate cancerProstate cancer riskProstate cancerHereditary prostate cancerBRCA2 mutationsFamily historyCancer riskNational Comprehensive Cancer Network guidelinesGenetic testingProstate cancer screeningFamily cancer historyProstate cancer patientsEarly-onset diseasePositive family historyFirst-degree relativesClustering of casesNetwork guidelinesColorectal cancerCancer historyCancer patientsCancer screeningCommon tumorsRisk factorsSurrogate markerOvarian cancer
2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers